Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Ultrasound mediated barrier opening
What ifWhat if focused ultrasound opened a localized route for a circulating peptide agonist that has no transport carrier?
Claim language“a transcytotic carrier”
A focused ultrasound transducer applies pulsed energy to a selected brain region after intravenous administration of lipid-shelled microbubbles. Microbubble oscillation transiently increases local blood-brain barrier permeability while the peptide agonist circulates in the blood.
1.1Direct infusion into brain tissue
What ifWhat if a catheter delivered the peptide agonist directly into brain tissue without a transport carrier?
Claim language“a transcytotic carrier”
A stereotactically placed catheter connects to a programmable pump that infuses an aqueous peptide solution into a selected brain region. The infusion creates a local pressure gradient that distributes the peptide through extracellular spaces around the catheter tip.
1.1Preservation of endogenous incretins
What ifWhat if an oral enzyme inhibitor prolonged endogenous incretin signaling without directly activating the glucagon-like peptide-1 receptor?
A small molecule inhibits dipeptidyl peptidase-4 and slows the cleavage of endogenous glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. The intact hormones sustain glucose-dependent insulin secretion after meals.
1.1Melanocortin receptor activation
What ifWhat if an injected peptide reduced food intake in a defined form of obesity by activating the melanocortin-4 receptor without activating either incretin receptor?
A subcutaneous formulation delivers a cyclic peptide that activates the melanocortin-4 receptor in appetite-regulating circuits. This receptor activation reduces hunger in obesity caused by defects in upstream melanocortin signaling.
1.1Free peptide in lipid vesicles
What ifWhat if an injectable lipid vesicle carried the peptide conjugate in free form without a stoichiometric counterion?
Phosphatidylcholine and cholesterol form vesicles around an aqueous phase containing the peptide conjugate. The vesicles release the conjugate into the surrounding fluid, where its attached transport moiety binds a receptor on brain endothelial cells.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Reference material for barrier assay training
A reference kit for laboratory training contains a purified transcytotic carrier conjugated to a GLP-1 receptor agonist and a matched sample of free agonist. Trainees load the two samples into separate donor wells above brain endothelial cell layers grown on porous inserts. They collect receiver samples and use liquid chromatography with mass spectrometry to distinguish intact conjugate from free agonist.
Component substitution
Covalent coupling through a triazole linker
A transcytotic carrier with a terminal azide couples to a GLP-1 receptor agonist bearing a dibenzocyclooctyne group on a side chain outside its receptor activation region. The two handles form a triazole linkage in aqueous buffer without a metal catalyst. Size-exclusion chromatography isolates the conjugate from free agonist, and a cyclic AMP assay measures receptor activation by the isolated conjugate.
Parameter or scale variation
Timed transfer measurements across donor concentrations
Replicate brain endothelial inserts receive the same carrier–agonist conjugate at donor concentrations of 10, 30, and 100 nanomolar. Separate replicate sets supply receiver samples at 15, 30, 60, and 120 minutes to keep chamber volumes constant during each exposure. The assay reports intact conjugate transferred per square centimeter of membrane and records electrical resistance before dosing and at the sampling endpoint.
Combination with existing systems
Barrier chip with a receptor reporter
A perfused barrier chip contains a brain endothelial channel and a receiver channel separated by a porous membrane. The vascular inlet supplies the carrier–agonist conjugate, and the receiver outlet feeds a chamber containing cells that express the GLP-1 receptor and a cyclic AMP reporter. A sampling port upstream of the reporter chamber supplies matched fractions for mass spectrometry to distinguish intact conjugate from released agonist.
Conjugate stability testing with peptide mapping
A plasma stability assay incubates the carrier–agonist conjugate alongside free agonist and a buffer-only conjugate control. Intact-mass analysis quantifies the conjugate in each timed sample, and tandem mass spectrometry maps cleavage sites in the carrier, linker region, and agonist. A matched aliquot from each time point enters a GLP-1 receptor reporter assay to track receptor activity as the molecular composition changes.
Automated or data-driven variant
Automated sampling with electrical barrier checks
A liquid-handling robot dispenses the carrier–agonist conjugate into a multiwell brain endothelial insert plate and collects receiver samples at programmed times. An electrode array measures electrical resistance across each insert before dosing and after the final sample. Software associates each receiver sample with its source well and flags wells whose endpoint resistance falls below the acceptance interval established by vehicle controls.
Specific version of a part
Single transferrin receptor binding arm
A recombinant fusion joins a glucagon-like peptide-1 receptor agonist to a monovalent transferrin receptor-binding antibody fragment through a glycine-serine linker. The fragment binds the receptor on brain endothelial cells and mediates uptake and transcytosis of the fusion.
Transport peptide with thioether linkage
A transporter peptide that binds low-density lipoprotein receptor-related protein 1 is coupled to a distal cysteine on a dual incretin agonist using a maleimide linker. The resulting thioether joins the two peptides while leaving the agonist’s amino terminus available for receptor activation.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1a transcytotic carrier conjugated to a glucagon-like-peptide-1 receptor agonist (“GLP-1rA”), a glucagon-like-peptide-1 and glucose-dependent insulinotropic polypeptide receptor dual agonist (“GLP-1/GIPrA”), or a pharmaceutically-acceptable salt thereof.
The multimers described herein can be conjugated to GLP-1 agonist known in the art.
A · US 9,161,988 B2 · ¶ 178
Fatty acids, through their albumin binding motifs, can improve the pharmacokinetics of a peptide by extending the half-life, for example. While use of fatty acids can improve peptide half-life, it was discovered by Applicants as part of the present invention that the length, composition, and placement of the fatty acid chain and the linker between the peptide and the fatty acid chain can have unexpected effects on the balancing of the GIP and GLP-1 agonist activity.
B · US 9,474,780 B2 · ¶ 9
An empty cell means only that no passage was reproduced there.
Statements in these documents
Therapy of brain diseases can be impaired by the inability of otherwise effective therapeutic agents to cross the BBB.
A · US 9,161,988 B2 · ¶ 4
When these compounds are joined with (e.g., conjugated to) one or more agents, efficiency of transport across the BBB or into particular cell types is likewise enhanced.
A · US 9,161,988 B2 · ¶ 5
A compound for T2D is needed that utilizes a dual mechanism of action.
B · US 9,474,780 B2 · ¶ 2
More particularly, the present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
B · US 9,474,780 B2 · ¶ 1
Cite aspatent.fyi, US 2026/0355286 A1, claim 1, first published 2026-11-19T09:44:02-05:00, https://patent.fyi/US20260355286/, SHA-256 354da9525580056fec0289f1c5067b9667380e5fa042f4198b9bd9f3cf23e56d